Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29269190 | 0.90 | DRD2 (0.51) | ALDH1A1XBP1HTTRAB9ADRD2 | |
| SCHEMBL12124883 | 0.88 | HTT (0.55) | ALDH1A1XBP1HTTRAB9ADRD2 | |
| SCHEMBL12609208 | 0.82 | HTT (0.48) | ALDH1A1XBP1HTTRAB9ADRD2 | |
| SCHEMBL1682368 | 0.82 | DRD2 (0.57) | ALDH1A1XBP1HTTRAB9ADRD2 | |
| SCHEMBL8843210 | 0.81 | CXCR4 (0.55) | DRD2CXCR4 | |
| SCHEMBL1132819 | 0.79 | TAS1R3 (0.40) | DRD2 | |
| SCHEMBL7784661 | 0.78 | CXCR4 (0.51) | DRD2CXCR4 | |
| SCHEMBL12124859 | 0.77 | HTT (0.57) | ALDH1A1XBP1HTTRAB9AMAOA | |
| SCHEMBL12124857 | 0.77 | HTT (0.57) | ALDH1A1XBP1HTTRAB9AMAOA | |
| SCHEMBL12124861 | 0.77 | HTT (0.57) | ALDH1A1XBP1HTTRAB9AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2287173-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152239-A1 | 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE | ELOVL3, ELOVL5, SCD5 | ALDH1A1 3050/4885XBP1 4627/4885HTT 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.